VVUS - VIVUS Stock Price, News & Analysis

$0.65 -0.01 (-1.52 %)
(As of 11/24/2017 11:25 AM ET)
Previous Close$0.66
Today's Range$0.65 - $0.67
52-Week Range$0.61 - $1.47
Volume484,700 shs
Average Volume724,761 shs
Market Capitalization$68.89 million
P/E Ratio1.91
Dividend YieldN/A
Beta0.82

About VIVUS (NASDAQ:VVUS)

VIVUS logoVIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company has completed the Phase II studies of Qsymia for the indication of Obstructive Sleep Apnea (OSA) and diabetes. Its Qsymia is available in over 40,000 certified retail pharmacies across the country. Its STENDRA is also approved by the European Commission (EC), under the name, SPEDRA, for the treatment of ED in the Europe. The United States Food and Drug Association approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.


Industry, Sector and Symbol

Industry Biopharmaceuticals
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:VVUS
CUSIP92855110

Debt

Debt-to-Equity Ratio643.86%
Current Ratio7.47%
Quick Ratio7.09%

Price-To-Earnings

Trailing P/E Ratio1.91
Forward P/E Ratio-2.03
P/E GrowthN/A

Sales & Book Value

Annual Sales$124.26 million
Price / Sales0.55
Cash Flow$0.42 per share
Price / Cash1.55
Book ValueN/A
Price / BookN/A

Dividend

Annual DividendN/A
Dividend YieldN/A

Profitability

Trailing EPS$0.34
Net Income$23.30 million
Net Margins26.71%
Return on Equity344.23%
Return on Assets12.56%

Miscellaneous

Employees65
Outstanding Shares105,950,000

Frequently Asked Questions for VIVUS (NASDAQ:VVUS)

What is VIVUS's stock symbol?

VIVUS trades on the NASDAQ under the ticker symbol "VVUS."

How were VIVUS's earnings last quarter?

VIVUS, Inc. (NASDAQ:VVUS) released its quarterly earnings data on Tuesday, November, 7th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.13) by $0.07. The biopharmaceutical company earned $15.19 million during the quarter, compared to analysts' expectations of $16 million. VIVUS had a net margin of 26.71% and a return on equity of 344.23%. The firm's quarterly revenue was up 13.8% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.09) EPS. View VIVUS's Earnings History.

Who are some of VIVUS's key competitors?

Who are VIVUS's key executives?

VIVUS's management team includes the folowing people:

  • David York Norton, Independent Chairman of the Board (Age 66)
  • Seth H. Z. Fischer, Chief Executive Officer, Chief Commercial Officer, Director (Age 61)
  • Mark K. Oki CPA, Chief Financial Officer, Chief Accounting Officer (Age 48)
  • John L. Slebir Esq., Senior Vice President - Business Development, General Counsel, Secretary (Age 50)
  • Santosh T. Varghese M.D., Chief Medical Officer (Age 47)
  • Thomas B. King, Independent Director (Age 62)
  • Jorge Plutzky M.D., Independent Director (Age 57)
  • Eric W. Roberts, Independent Director (Age 53)
  • Herman Rosenman CPA, Independent Director (Age 70)
  • Allan L. Shaw, Independent Director (Age 53)

Who owns VIVUS stock?

VIVUS's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include OxFORD Asset Management LLP (1.00%), Russell Investments Group Ltd. (0.37%) and Macquarie Group Ltd. (0.18%). Company insiders that own VIVUS stock include John L Slebir, North Tide Capital, Llc and Santosh T Varghese. View Institutional Ownership Trends for VIVUS.

Who bought VIVUS stock? Who is buying VIVUS stock?

VIVUS's stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Macquarie Group Ltd. and OxFORD Asset Management LLP. View Insider Buying and Selling for VIVUS.

How do I buy VIVUS stock?

Shares of VIVUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is VIVUS's stock price today?

One share of VIVUS stock can currently be purchased for approximately $0.65.

How big of a company is VIVUS?

VIVUS has a market capitalization of $68.89 million and generates $124.26 million in revenue each year. The biopharmaceutical company earns $23.30 million in net income (profit) each year or $0.34 on an earnings per share basis. VIVUS employs 65 workers across the globe.

How can I contact VIVUS?

VIVUS's mailing address is 900 E. HAMILTON AVENUE SUITE 550, CAMPBELL CA, 95008. The biopharmaceutical company can be reached via phone at 650-934-5200 or via email at [email protected]


MarketBeat Community Rating for VIVUS (VVUS)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  225 (Vote Outperform)
Underperform Votes:  273 (Vote Underperform)
Total Votes:  498
MarketBeat's community ratings are surveys of what our community members think about VIVUS and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for VIVUS (NASDAQ:VVUS)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Analysts' Consensus Price Target: N/A

Consensus Price Target History for VIVUS (NASDAQ:VVUS)

Price Target History for VIVUS (NASDAQ:VVUS)

Analysts' Ratings History for VIVUS (NASDAQ:VVUS)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/25/2016WallachBeth CapitalSet Price TargetBuy$2.80N/AView Rating Details
5/4/2016J P Morgan Chase & CoReiterated RatingHoldN/AView Rating Details
3/10/2016Needham & Company LLCReiterated RatingHoldN/AView Rating Details
2/29/2016Royal Bank Of CanadaDowngradeOutperform -> Sector Perform$4.00 -> $1.00N/AView Rating Details
(Data available from 11/24/2015 forward)

Earnings

Earnings History and Estimates Chart for VIVUS (NASDAQ:VVUS)

Earnings by Quarter for VIVUS (NASDAQ:VVUS)

Earnings History by Quarter for VIVUS (NASDAQ VVUS)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017Q3 2017($0.13)($0.06)$16.00 million$15.19 millionViewN/AView Earnings Details
5/3/2017Q1 2017($0.13)($0.01)$27.01 millionViewListenView Earnings Details
3/8/2017Q4 2016$0.23$0.54$48.82 million$81.81 millionViewListenView Earnings Details
11/9/2016Q316($0.19)($0.09)$21.91 million$13.40 millionViewListenView Earnings Details
8/4/2016Q216($0.31)($0.11)$19.00 million$13.77 millionViewN/AView Earnings Details
5/3/2016Q116($0.21)($0.12)$17.97 million$15.32 millionViewN/AView Earnings Details
3/9/2016Q4($0.12)($0.12)$22.90 million$15.34 millionViewN/AView Earnings Details
11/4/2015Q315($0.17)($0.15)$20.24 million$24.90 millionViewN/AView Earnings Details
7/30/2015Q215($0.23)($0.19)$18.76 million$23.00 millionViewListenView Earnings Details
5/5/2015Q115($0.22)($0.15)$21.80 million$32.20 millionViewN/AView Earnings Details
2/24/2015Q414($0.25)($0.25)$20.00 million$21.70 millionViewListenView Earnings Details
11/5/2014Q314($0.25)($0.10)$21.90 million$33.90 millionViewListenView Earnings Details
8/7/2014Q214($0.28)($0.25)$17.90 million$21.90 millionViewListenView Earnings Details
5/5/2014Q114($0.37)($0.15)$11.40 million$36.70 millionViewN/AView Earnings Details
2/24/2014Q413($0.40)($0.17)$28.20 million$44.06 millionViewListenView Earnings Details
11/5/2013Q313($0.38)($0.48)$21.78 million$27.38 millionViewN/AView Earnings Details
8/6/2013Q2 2013($0.44)($0.55)$12.76 million$5.53 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.51)($0.53)$5.22 million$4.10 millionViewN/AView Earnings Details
2/25/2013Q4 2012($0.44)($0.56)$3.09 million$1.97 millionViewN/AView Earnings Details
11/6/2012Q312($0.34)($0.40)$0.35 million$0.04 millionViewN/AView Earnings Details
8/7/2012($0.23)($0.24)ViewN/AView Earnings Details
5/7/2012($0.13)($0.20)ViewN/AView Earnings Details
2/28/2012($0.12)($0.14)ViewN/AView Earnings Details
11/7/2011($0.12)($0.10)ViewN/AView Earnings Details
8/1/2011($0.13)($0.20)ViewN/AView Earnings Details
5/2/2011($0.15)($0.12)ViewN/AView Earnings Details
2/28/2011($0.22)($0.23)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for VIVUS (NASDAQ:VVUS)
Current Year EPS Consensus Estimate: $-0.32 EPS
Next Year EPS Consensus Estimate: $-0.45 EPS

Dividends

Dividend History for VIVUS (NASDAQ:VVUS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for VIVUS (NASDAQ VVUS)

Insider Ownership Percentage: 4.40%
Institutional Ownership Percentage: 36.86%
Insider Trades by Quarter for VIVUS (NASDAQ:VVUS)
Institutional Ownership by Quarter for VIVUS (NASDAQ:VVUS)

Insider Trades by Quarter for VIVUS (NASDAQ VVUS)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/3/2017Santosh T VargheseInsiderSell434$0.97$420.98View SEC Filing  
7/3/2017Santosh T VargheseInsiderSell423$1.23$520.29View SEC Filing  
4/4/2017Santosh T VargheseInsiderSell440$1.08$475.20View SEC Filing  
3/10/2017North Tide Capital, LlcMajor ShareholderSell1,149,400$1.16$1,333,304.00View SEC Filing  
3/7/2017North Tide Capital, LlcMajor ShareholderSell192,800$1.08$208,224.00View SEC Filing  
3/2/2017North Tide Capital, LlcMajor ShareholderSell160,100$1.13$180,913.00View SEC Filing  
2/27/2017North Tide Capital, LlcMajor ShareholderSell333,000$1.14$379,620.00View SEC Filing  
2/22/2017North Tide Capital, LlcMajor ShareholderSell161,800$1.11$179,598.00View SEC Filing  
2/16/2017North Tide Capital, LlcMajor ShareholderSell305,090$1.10$335,599.00View SEC Filing  
2/13/2017North Tide Capital, LlcMajor ShareholderSell176,410$1.11$195,815.10View SEC Filing  
2/8/2017North Tide Capital, LlcMajor ShareholderSell563,527$1.06$597,338.62View SEC Filing  
2/7/2017North Tide Capital, LlcMajor ShareholderSell6,200$1.11$6,882.00View SEC Filing  
2/6/2017North Tide Capital, LlcMajor ShareholderSell28,027$1.10$30,829.70View SEC Filing  
2/3/2017North Tide Capital, LlcMajor ShareholderSell78,633$1.12$88,068.96View SEC Filing  
1/28/2017Santosh T VargheseInsiderSell429$1.11$476.19View SEC Filing  
12/31/2016Santosh T VargheseInsiderSell13,790$1.12$15,444.80View SEC Filing  
10/1/2016Santosh T VargheseInsiderSell710$1.14$809.40View SEC Filing  
8/2/2016Santosh T VargheseInsiderSell12,559$1.07$13,438.13View SEC Filing  
7/1/2016Santosh T VargheseVPSell366$1.21$442.86View SEC Filing  
4/7/2016Santosh T VargheseInsiderSell329$1.65$542.85View SEC Filing  
4/1/2016North Tide Capital, LlcMajor ShareholderBuy2,160$1.40$3,024.00View SEC Filing  
3/31/2016North Tide Capital, LlcMajor ShareholderBuy383,300$1.29$494,457.00View SEC Filing  
3/28/2016North Tide Capital, LlcMajor ShareholderBuy202,000$1.12$226,240.00View SEC Filing  
3/16/2016North Tide Capital, LlcMajor ShareholderBuy500,000$1.21$605,000.00View SEC Filing  
1/1/2016John L SlebirSVPSell2,973$3.04$9,037.92View SEC Filing  
1/8/2015North Tide Capital, LlcMajor ShareholderBuy500,000$3.12$1,560,000.00View SEC Filing  
1/6/2015North Tide Capital, LlcMajor ShareholderBuy476,800$3.04$1,449,472.00View SEC Filing  
1/2/2015North Tide Capital, LlcMajor ShareholderBuy523,200$2.90$1,517,280.00View SEC Filing  
3/11/2014Seth H.Z. FischerCEOBuy3,080$6.07$18,695.60View SEC Filing  
11/11/2013Alexander DennerDirectorBuy566,844$8.59$4,869,189.96View SEC Filing  
9/5/2013Timothy E MorrisCFOSell10,654$11.95$127,315.30View SEC Filing  
9/4/2013Michael J AstrueDirectorBuy10,000$11.96$119,600.00View SEC Filing  
6/27/2013Jon C BiroInsiderBuy2,000$12.85$25,700.00View SEC Filing  
5/29/2013Ernest MarioDirectorBuy15,000$14.68$220,200.00View SEC Filing  
8/20/2012Ernest MarioDirectorBuy5,000$20.75$103,750.00View SEC Filing  
8/10/2012Ernest MarioDirectorBuy20,000$21.74$434,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for VIVUS (NASDAQ VVUS)

Source:
DateHeadline
ETFs with exposure to VIVUS, Inc. : November 20, 2017ETFs with exposure to VIVUS, Inc. : November 20, 2017
finance.yahoo.com - November 20 at 4:02 PM
 Analysts Anticipate VIVUS, Inc. (VVUS) Will Post Earnings of -$0.13 Per Share Analysts Anticipate VIVUS, Inc. (VVUS) Will Post Earnings of -$0.13 Per Share
www.americanbankingnews.com - November 17 at 1:38 PM
ETFs with exposure to VIVUS, Inc. : November 10, 2017ETFs with exposure to VIVUS, Inc. : November 10, 2017
finance.yahoo.com - November 12 at 1:16 PM
Edited Transcript of VVUS earnings conference call or presentation 7-Nov-17 9:30pm GMTEdited Transcript of VVUS earnings conference call or presentation 7-Nov-17 9:30pm GMT
finance.yahoo.com - November 9 at 9:43 AM
VIVUS, Inc. :VVUS-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017VIVUS, Inc. :VVUS-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017
finance.yahoo.com - November 9 at 9:43 AM
VIVUS, Inc. (VVUS) Releases  Earnings Results, Beats Estimates By $0.07 EPSVIVUS, Inc. (VVUS) Releases Earnings Results, Beats Estimates By $0.07 EPS
www.americanbankingnews.com - November 8 at 7:11 PM
Vivus reports 3Q lossVivus reports 3Q loss
finance.yahoo.com - November 7 at 6:25 PM
VIVUS Reports Third Quarter 2017 Financial ResultsVIVUS Reports Third Quarter 2017 Financial Results
feeds.benzinga.com - November 7 at 4:43 PM
VIVUS, Inc. to Host Earnings CallVIVUS, Inc. to Host Earnings Call
finance.yahoo.com - November 7 at 1:24 PM
VIVUS Completes Tacrolimus Pre-IND Meeting With FDAVIVUS Completes Tacrolimus Pre-IND Meeting With FDA
finance.yahoo.com - November 2 at 11:13 AM
ETFs with exposure to VIVUS, Inc. : October 30, 2017ETFs with exposure to VIVUS, Inc. : October 30, 2017
finance.yahoo.com - October 31 at 12:01 PM
VIVUS, Inc. (VVUS) Set to Announce Quarterly Earnings on TuesdayVIVUS, Inc. (VVUS) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - October 31 at 8:52 AM
VIVUS to Host Third Quarter Business Update and Financial Results Conference Call on Tuesday, November 7, 2017VIVUS to Host Third Quarter Business Update and Financial Results Conference Call on Tuesday, November 7, 2017
feeds.benzinga.com - October 31 at 8:50 AM
ETFs with exposure to VIVUS, Inc. : October 20, 2017ETFs with exposure to VIVUS, Inc. : October 20, 2017
finance.yahoo.com - October 20 at 4:34 PM
Financial Review: VIVUS (VVUS) vs. The CompetitionFinancial Review: VIVUS (VVUS) vs. The Competition
www.americanbankingnews.com - October 17 at 8:26 AM
VIVUS (VVUS) and Sinovac Biotech (SVA) Head to Head ReviewVIVUS (VVUS) and Sinovac Biotech (SVA) Head to Head Review
www.americanbankingnews.com - October 12 at 10:32 PM
ETFs with exposure to VIVUS, Inc. : October 9, 2017ETFs with exposure to VIVUS, Inc. : October 9, 2017
finance.yahoo.com - October 10 at 8:14 AM
Critical Contrast: VIVUS (VVUS) versus Its PeersCritical Contrast: VIVUS (VVUS) versus Its Peers
www.americanbankingnews.com - October 9 at 6:28 PM
VIVUS, Inc. :VVUS-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017VIVUS, Inc. :VVUS-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017
finance.yahoo.com - October 6 at 12:42 PM
Argos Therapeutics (ARGS) & VIVUS (VVUS) Head-To-Head SurveyArgos Therapeutics (ARGS) & VIVUS (VVUS) Head-To-Head Survey
www.americanbankingnews.com - September 29 at 12:34 PM
Orexigens (OREX) Contrave Sales Improving on PromotionsOrexigen's (OREX) Contrave Sales Improving on Promotions
www.zacks.com - September 28 at 10:20 AM
Critical Survey: VIVUS (VVUS) versus Its RivalsCritical Survey: VIVUS (VVUS) versus Its Rivals
www.americanbankingnews.com - September 18 at 2:26 AM
VIVUS, Inc. (VVUS) Sees Large Drop in Short InterestVIVUS, Inc. (VVUS) Sees Large Drop in Short Interest
www.americanbankingnews.com - September 15 at 1:28 AM
VIVUS (VVUS) Says Tacrolimus Received Orphan Drug Designation in the European Union for the Treatment of PAHVIVUS (VVUS) Says Tacrolimus Received Orphan Drug Designation in the European Union for the Treatment of PAH
www.streetinsider.com - September 8 at 10:10 AM
VIVUS, Aggressive Marketing For Approved Drugs, Milestone for Tacrolimus, Pipeline AnalysisVIVUS, Aggressive Marketing For Approved Drugs, Milestone for Tacrolimus, Pipeline Analysis
finance.yahoo.com - September 8 at 10:10 AM
VIVUS Announces Tacrolimus Receives Orphan Drug Designation in the European Union for the Treatment of Pulmonary Arterial HypertensionVIVUS Announces Tacrolimus Receives Orphan Drug Designation in the European Union for the Treatment of Pulmonary Arterial Hypertension
finance.yahoo.com - September 7 at 11:05 AM
VIVUS (VVUS), Alvogen Announce Marketing Agreement for Qsymia in Republic of Korea - StreetInsider.comVIVUS (VVUS), Alvogen Announce Marketing Agreement for Qsymia in Republic of Korea - StreetInsider.com
www.streetinsider.com - September 6 at 10:09 AM
VIVUS and Alvogen Announce Marketing Agreement for Qsymia(R) in the Republic of KoreaVIVUS and Alvogen Announce Marketing Agreement for Qsymia(R) in the Republic of Korea
finance.yahoo.com - September 6 at 10:09 AM
VIVUS (VVUS) Down 19.8% Since Earnings Report: Can It Rebound?VIVUS (VVUS) Down 19.8% Since Earnings Report: Can It Rebound?
finance.yahoo.com - September 4 at 3:41 PM
VIVUS (VVUS) and Alimera Sciences (ALIM) Head to Head SurveyVIVUS (VVUS) and Alimera Sciences (ALIM) Head to Head Survey
www.americanbankingnews.com - September 2 at 10:24 PM
VIVUS, Inc. (VVUS) Expected to Announce Earnings of -$0.13 Per ShareVIVUS, Inc. (VVUS) Expected to Announce Earnings of -$0.13 Per Share
www.americanbankingnews.com - September 2 at 2:26 AM
VIVUS (VVUS) Settles with Dr. Reddys Laboratories on Qsymia ... - StreetInsider.comVIVUS (VVUS) Settles with Dr. Reddy's Laboratories on Qsymia ... - StreetInsider.com
www.streetinsider.com - August 31 at 1:57 AM
VIVUS Announces Settlement with Dr. Reddys Laboratories on Qsymia(R) Patent LitigationVIVUS Announces Settlement with Dr. Reddy's Laboratories on Qsymia(R) Patent Litigation
finance.yahoo.com - August 30 at 8:54 PM
Vivid Potential Victory With Vivus, Inc. Convertible Bonds - Seeking AlphaVivid Potential Victory With Vivus, Inc. Convertible Bonds - Seeking Alpha
seekingalpha.com - August 23 at 1:46 PM
VIVUS to Present at 2017 Wells Fargo Healthcare Conference on September 7, 2017VIVUS to Present at 2017 Wells Fargo Healthcare Conference on September 7, 2017
finance.yahoo.com - August 23 at 1:46 PM
Critical Review: VIVUS (VVUS) & Tokai Pharmaceuticals (NVUS)Critical Review: VIVUS (VVUS) & Tokai Pharmaceuticals (NVUS)
www.americanbankingnews.com - August 19 at 8:44 AM
Vivus Pipeline Review, Analysis and Potential CatalystsVivus Pipeline Review, Analysis and Potential Catalysts
finance.yahoo.com - August 10 at 9:34 AM
VIVUS (VVUS) Q2 Loss In Line with Estimates, Sales Down Y/Y - NasdaqVIVUS (VVUS) Q2 Loss In Line with Estimates, Sales Down Y/Y - Nasdaq
www.nasdaq.com - August 9 at 8:59 AM
VIVUS (VVUS) Q2 Loss In Line with Estimates, Sales Down Y/YVIVUS (VVUS) Q2 Loss In Line with Estimates, Sales Down Y/Y
finance.yahoo.com - August 8 at 8:15 AM
Peregrine Pharmaceuticals (PPHM) & VIVUS (VVUS) Head-To-Head AnalysisPeregrine Pharmaceuticals (PPHM) & VIVUS (VVUS) Head-To-Head Analysis
www.americanbankingnews.com - August 5 at 8:36 PM
VIVUS Reports Second Quarter 2017 Financial ResultsVIVUS Reports Second Quarter 2017 Financial Results
feeds.benzinga.com - August 3 at 4:34 PM
-$0.13 EPS Expected for VIVUS, Inc. (NASDAQ:VVUS) This Quarter-$0.13 EPS Expected for VIVUS, Inc. (NASDAQ:VVUS) This Quarter
www.americanbankingnews.com - July 27 at 11:17 AM
VIVUS, Inc. (NASDAQ:VVUS) Set to Announce Earnings on WednesdayVIVUS, Inc. (NASDAQ:VVUS) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - July 26 at 7:48 AM
VIVUS Announces Settlement with Actavis on Qsymia(R) Patent LitigationVIVUS Announces Settlement with Actavis on Qsymia(R) Patent Litigation
finance.yahoo.com - July 6 at 5:16 PM
VIVUS, Inc. (NASDAQ:VVUS) Expected to Announce Earnings of -$0.13 Per ShareVIVUS, Inc. (NASDAQ:VVUS) Expected to Announce Earnings of -$0.13 Per Share
www.americanbankingnews.com - July 3 at 10:14 AM
VIVUS (VVUS) Names Thomas King to Board of Directors - StreetInsider.comVIVUS (VVUS) Names Thomas King to Board of Directors - StreetInsider.com
www.streetinsider.com - May 26 at 8:31 AM
5 Reasons Why VIVUS, Inc. (VVUS) Stock Should Be in Your Portfolio - Investorplace.com5 Reasons Why VIVUS, Inc. (VVUS) Stock Should Be in Your Portfolio - Investorplace.com
investorplace.com - May 26 at 8:31 AM
5 Reasons Why VIVUS, Inc. (VVUS) Stock Should Be in Your Portfolio5 Reasons Why VIVUS, Inc. (VVUS) Stock Should Be in Your Portfolio
investorplace.com - May 25 at 7:48 AM
Vivus (VVUS) CEO Seth Fischer on Q1 2017 Results - Earnings Call TranscriptVivus' (VVUS) CEO Seth Fischer on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 3 at 11:55 PM
VIVUS Announces Date of 2017 First Quarter Business Update and Financial Results TeleconferenceVIVUS Announces Date of 2017 First Quarter Business Update and Financial Results Teleconference
feeds.benzinga.com - April 25 at 8:19 AM

Social Media

Financials

Chart

VIVUS (NASDAQ VVUS) Chart for Friday, November, 24, 2017
Loading chart…

This page was last updated on 11/24/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.